Thedevelopmentofinnovativeskincareproductsrequiresadvanced,human-relevantinvitrotestingtechnologies.WhenworldleADIngpersonalcareandcosmeticscientistsevaluatenovelingredientsandformulations,theychoosetheEpiDermFT3Dhumanskinmodel.
- LargeDonorInventorywithMatchedKeratinocytesandFibroblasts
- AdultorNeonatalDonorsareAvailable
- DeliveredReady-to-Use
Technology:
Engineeredtoenableinvitroskinresearchinwhichfibroblast-keratinocytecellinteractionsareimportant,MatTek’sEpiDermFTsystemconsistsofnormal,humanepidermalkeratinocytes(NHEK)andnormal,humandermalfibroblasts(NHFB)culturedtoformamultilayeredmodelofthehumandermisandepidermis.Culturedattheair-liquidinterfaceineasy-to-handletissuecultureinserts,EpiDermFTattainslevelsofdifferentiationatthecuttingedgeoftissueengineeringtechnology.
EpiDermFTconsistsoforganizedkeratin5expressingbasalcells,involucrinandkeratin10expressingspinousandgranularlayers,andcornifiedepidermallayersanalogoustothosefoundinvivo.Thedermalcompartmentiscomposedofacollagenmatrixcontainingviablenormalhumandermalfibroblasts(NHDF).Theepidermalanddermallayersaremitoticallyandmetabolicallyactiveandexhibitinvivo-likemorphologicalandgrowthcharacteristicswhichareuniformandhighlyreproducIBLe.
Awell-developedbasementmembraneispresentatthedermal/epidermaljunction.Hemidesomosomes(›),laminalucida,laminadensa(→)andanchoringfibrilstructures(»)areevidentbytransmissionelectronmicroscopy.
Applications:
EpiDermFTtissuesareusedacrossawiderangeofapplicationsincludingscientificefficacyandclaimssubstantiation.Duetoadryskinsurface,EpiDermFTcanbeusedtoevaluateBIOLOGicalresponsestotopicalapplicationsofformulationsoringredients.Simpleprotocolsandtheevaluationofearlymolecularendpointsallowresearchtoacquiredataindays,notweeksormonths.
Anti-Aging
Examinechangesinextracellularmatrixgeneandproteinexpressionandhistologicalstructuretodeterminetheanti-agingefficacyofcosmeticingredientsorfinalformulation.EpiDermFTisavailablefromarangeofadultdonors.
Anti-AgingApplicationNote
WoundHealing
UseEpiDermFTtoevaluatetherapeuticswiththewoundhealingassaykit.Woundhealingassaykitsinclude24pre-woundedtissuesandareavailablewithepidermalonlywoundsorfullthicknesswoundsoftheepidermisanddermis.
RecentWoundHealingPoster
SkinHydration
UseEpiDermFTtoassesstheefficacyoftopicallyappliedmoisturizersbymeasuringtheelectricalimpedanceoftheepidermis.Amenabletocreams,gel,lotionsorotherformulations,theSkinHydrationassayallowsfordataanalysiswithin24hours.
SkinHydrationApplicationNote
UVProtection
Analyzecyclopyrimidinedimerformation,inflammatorymediatorreleaseandoxidativeendpointstoevaluatetheUVprotectiveefficacyofcompoundsorformulations.
UVProtection ApplicationNote
BrowseourreferencelibrarytoseehowourEpiDermFT tissuehasbeenusedintheseareasofstudy.
TechSpecs:
Tissue
Kit: AstandardEpiDermFTkit(EFT-400)consistsof24tissues.(Tissue“kits”containtissues,asmallamountofculturemedium,andplasticware;contactMatTekforspecifickitcontents)
Substrate: CostarSnapwell™singlewelltissuecultureplateinserts areused.Poresize=0.4μm,Diameter=1.2cm.Surfacearea=1.0cm2
Culture: Air-liquidinterface
Histology: 8-12celllayersplusstratumcorneum(basal,spinous,andgranularlayers)
Lotnumbers: Tissuelotsproducedeachweekareassignedaspecificlotnumber.Aletterofthealphabetisappendedtotheendofthelotnumbertodifferentiatebetweenindividualkitswithinagivenlotoftissues.Alltissuekitswithinalotareidenticalinregardstocells,medium,handling,cultureconditions,etc.
Shipment: At4°Conmedium-supplemented,agarosegelsin6-wellplates
Shipmentday: EveryMonday.ShipmentonThursdayalsopossibleuponspecialrequest
Delivery: TuesdaymorningviaFedExpriorityservice(US).OutsideUS:Tuesday-Thursdaydependingonlocation
Shelflife: Includingtimeintransit,tissuesmaybestoredat4°Cforupto6dayspriortouse.However,extendedstorageperiodsarenotrecommendedunlessnecessary.Inaddition,thebestreproducibilitywillbeobtainediftissuesareusedconsistentlyonthesameday,e.g.Tuesdayafternoonorfollowingovernightstorageat4°C(Wednesdaymorning)
Lengthofexperiments: Culturescanbecontinuedforupto2weekswithgoodretentionofnormalepidermalmorphology.Culturesmustbefedeveryotherdaywith5.0mlofEFT-400medium
Cells
Type: Normalhumanepidermalkeratinocytes(NHEK);Normalhumandermalfibroblasts(NHDF)
Geneticmake-up: Singledonor
Derivedfrom: Neonatal-foreskintissue(NHEK);Neonatalskin(NHDF)
Alternatives: NHEKfromadultbreastskin;NHDFfromadultskin
Screenedfor: HIV,Hepatitis-B,Hepatitis-C,mycoplasma
Medium
Basemedium: Dulbecco’sModifiedEagle’sMedium(DMEM)
Growthfactors/hormones: Epidermalgrowthfactor,insulin,hydrocortisoneandotherproprietarystimulatorsofepidermaldifferentiation
Serum: None
Antibiotics: Gentamicin5µg/ml(10%ofnormalgentamicinlevel)
Anti-fungalagent: AmphotericinB0.25µg/ml
pHIndicator: Phenolred
Otheradditives: Lipidprecursorsusedtoenhanceepidermalbarrierformation(proprietary)
Alternatives: Phenolred-free(EFT-400-PRF),antibiotic-free(EFT-400-ABF),anti-fungal-free(EFT-400-AFF),orhydrocortisone-freemediumandtissue(EFT-400-HCF)areavailable.Agentsareremovedatleast3dayspriortoshipment
Assay/Maintenancemedium: EFT-400-ASYisutilizedforassays;EFT-400-MMisusedfortermmaintenanceoftheEFT-400tissues
QualityControlandSterility
Visualinspection: Alltissuesarevisuallyinspectedandifphysicalimperfectionsarenoted,tissuesarerejectedforshipment
End-usetesting: Tissuesareexposedto1%TritonX-100for8,12,16and24hours.ThetimeofexposurerequiredtoreducethetissueviABIlity(ET-50)usingtheMTTviabilityassayisdetermined(SeeMatTekEpiDermFTuseprotocol)foreachlotoftissue.ET-50’sgenerallyfallwithintherangeof6.5-9.5hours.ET-50’sincustomers’labmaydifferslightlyfromtheMatTekresults
Sterility: Allmediausedthroughouttheproductionprocessischeckedforsterility.Maintenancemediumisincubatedwithandwithoutantibioticsfor1weekandcheckedforsterility.Theagarosegelfromthe24-wellplateusedforshippingisalsoincubatedfor1weekandcheckedforanysignofcontamination
Screeningforpathogens: AllcellsarescreenedandarenegativeforHIV,hepatitisBandhepatitisCusingPCR.However,noknowntestmethodcanoffercompleteassurancethatthecellsarepathogenfree.Thus,theseproductsandallhumanderivedproductsshouldbehandledatBSL-2levels(biosafetylevel2)orhigherasrecommendedintheCDC-NIHmanual,“Biosafetyinmicrobiologicalandbiomedicallaboratories,”1998.Forfurtherassistance,pleasecontactyoursiteSafetyOfficerorMatTektechnicalservice
Notificationoflotfailure: IfatissuelotfailsourQCorsterilitytesting,thecustomerwillbenotifiedandthetissueswillbereplacedwithoutchargewhenappropriate.BecauseourQCandsterilitytestingisdonepost-shipment,notificationwillbemadeassoonaspossible(Undernormalcircumstances,ET-50failureswillbenotifiedbyWednesday5p.m.;sterilityfailureswillbenotifiedwithin8daysofshipment)
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
①持续分裂细胞,又称周期性细胞, 即在细胞周期中连续运转的细胞。机体内某些组织需要不断的更新,组成这些组织的细胞就必须通过不断分裂产生新细胞。此类细胞的分裂周期非常正常, 有丝分裂的活性很高。如性细胞(包括卵母细胞和精原细胞),它们要不断地产生配子; 造血干细胞需要不断地产生红细胞和白细胞;上皮基底层细胞需要通过分裂不断补充表面老化死亡的细胞; 植物的根茎尖端细胞需要通过分裂进行生长等都是具有正常周期的持续分裂细胞。
②终端分化细胞, 即永久性失去了分裂能力的细胞,它们不可逆地脱离了细胞周期, 但保持了生理活性机能。这些细胞都是高度特化的细胞, 如哺乳动物的红细胞、神经细胞、多形性白细胞、肌细胞等, 这些细胞一旦分化,就永远保持这种不分裂状态直到死亡。
③G0细胞,又称休眠细胞,暂时脱离细胞周期,不进行DNA复制和分裂, 也称静止细胞群。但这些细胞可在某些条件的诱导下重新开始DNA合成, 进行细胞分裂。如肝细胞, 外科手术切除部分肝组成后可以诱导进入细胞分裂。淋巴细胞可通过与抗原的相互作用诱导增殖。在胚胎发育早期(卵裂期),所有的细胞均为周期性细胞, 以后随着发育成熟, 某些细胞进入了GO期, 某些细胞分化后丧失分裂能力。到成体时,只有少数细胞处于增殖状态, 它们的增殖仅作为补充丢失的细胞, 或对外界刺激的反应。
比如用CD3、CD28刺激,除了这个还有什么方法吗?增殖!
and还想问问用CD3、CD28刺激是不是所有T细胞都能增殖?
原核生物比如大肠杆菌促进增殖药物还不如提供更好的营养条件、足够的环境;抑制类药物如上。
根据细胞种类不同,可能需要不同成分的培养液,来达到促进/抑制的作用
细胞分化,产生的是不同的细胞,例如造血干细胞可以分化出红细胞。
本研究从新合成的十种核苷类似物中筛选具有抗肿瘤活性的化合物, 观察其抑制肿瘤细胞增殖、诱导细胞凋亡的作用,并探讨可能的作用机制。